Jan 26, 2021
Wholly owned by Nestlé and known by the name Nestlé Skin Health since 2014, Galderma was recently divested by the global food giant in a deal valued at 10.2 billion Swiss francs.
New ownership immediately set out to refocus the company as a pure-play dermatology business, restoring the Galderma brand and appointing new leadership, namely CFO Thomas Dittrich and CEO Flemming Ørnskov.
Ørnskov stands among the highest-profile execs in biopharma today. He initially built a reputation for himself as an executive at Bausch & Lomb and Bayer, among others but he is best known for his work as CEO of Shire, where he was credited with growing revenue more than three times over before leading the biotechnology company to a 62-billion-dollar buy out by Japanese multinational pharma company, Takeda.
Dr. Grant Stevens, recently sat down with Dr. Ørnskov for a candid and exclusive interview, in which the new CEO provided a glimpse into his vision and plans for the future of the world's largest independent global dermatology company.